Compare TG Therapeutics Inc (TGTX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Texas Instruments Incorporated — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Texas Instruments Incorporated trades at $283.74 (market cap $263.20B). The key difference: Texas Instruments Incorporated is far larger — about 32.3× TG Therapeutics Inc's market cap, and Texas Instruments Incorporated pays a 2.11% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Texas Instruments Incorporated for 76 Days on average.
| TGTX | TXN | |
|---|---|---|
Market Cap | $8.16B | $263.20B |
Volume | 1,735,121 | 5,850,256 |
Sector | Health | Technology |
52-Week High | $59.06 | $332.35 |
52-Week Low | $26.94 | $153.33 |
Typical Hold Time | 16 Days | 76 Days |
Enterprise Value | $8.37B | $270.25B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
Texas Instruments (TXN) trades at $288.20, down 0.26% on the day, with strong technical momentum showing bullish moving averages and key support at $284. The company demonstrates robust fundamentals with 31.11% net margins and 34.97% ROE, though valuation ratios remain elevated with a P/E of 43.8. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss, while data center sales growth and dividend payments highlight ongoing shareholder returns.
Outlook remains positive with analyst consensus targeting $325 (13% upside) amid accelerating revenue growth and AI-driven demand. Key risks include premium valuation sensitivity, cyclical semiconductor exposure, and rising debt levels. Institutional sentiment is bullish with 48% buy ratings, supported by strong cash flow generation and strategic positioning in industrial and data center markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
